These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9544622)

  • 1. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural characterization of contaminants in commercial preparations of melatonin by on-line HPLC-electrospray ionization-tandem mass spectrometry.
    Naylor S; Johnson KL; Williamson BL; Klarskov K; Gleich GJ
    Adv Exp Med Biol; 1999; 467():769-77. PubMed ID: 10721130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.
    Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S
    Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan.
    Klarskov K; Johnson KL; Benson LM; Cragun JD; Gleich GJ; Wrona M; Jiang XR; Dryhurst G; Naylor S
    J Rheumatol; 2003 Jan; 30(1):89-95. PubMed ID: 12508395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of 5-hydroxy-L-tryptophan.
    Das YT; Bagchi M; Bagchi D; Preuss HG
    Toxicol Lett; 2004 Apr; 150(1):111-22. PubMed ID: 15068828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
    Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
    Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
    Müller B; Pacholski C; Simat T; Steinhart H
    Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contaminants in biotechnologically manufactured L-tryptophan.
    Simat T; van Wickern B; Eulitz K; Steinhart EH
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.
    Belongia EA; Hedberg CW; Gleich GJ; White KE; Mayeno AN; Loegering DA; Dunnette SL; Pirie PL; MacDonald KL; Osterholm MT
    N Engl J Med; 1990 Aug; 323(6):357-65. PubMed ID: 2370887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness.
    Hatch DL; Goldman LR
    Arch Intern Med; 1993 Oct; 153(20):2368-73. PubMed ID: 8215741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
    Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S
    Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.